471 Risk of psoriatic arthritis in psoriasis patients on biologics and methotrexate

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis characterized by joint and entheseal inflammation seen in 30% patients with psoriasis (PsO). Inhibitors of tumor necrosis factor and interleukin 23 and 17 (‘biologics’) are efficacious treatment options for both. We aimed to determine if the use of either systemic non-biologic or biologic therapy decreases the risk of incident PsA in patients with PsO. Records on all PsO patients seen at dermatology clinic from January 2006 - June 2019 were reviewed.